{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:44Z","timestamp":1787003564893,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2017R1C1B2004989"],"award-info":[{"award-number":["2017R1C1B2004989"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2B2005390"],"award-info":[{"award-number":["2018R1A2B2005390"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatitis C virus (HCV) is the major causative agent of chronic liver diseases, including liver cirrhosis and hepatocellular carcinoma. The recent development of highly effective direct-acting antivirals (DAAs) has revolutionized the treatment of HCV patients. However, these DAAs are exorbitantly expensive for the majority of HCV patients worldwide. Moreover, these drugs still show genotypic difference in cure rate and have some resistant-associated variants. Tylophorine, a natural compound derived from\n                    <jats:italic>Tylophora indica<\/jats:italic>\n                    plants, is known to have anti-inflammatory and anti-cancerous growth activities. In the present study, we showed that two tylophorine intermediates, 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl) methyl]-L-proline (O859585) and 2,3,6,7-tetramethoxy-9-phenanthrenecarboxylic acid (T298875), displayed anti-HCV activity with an EC\n                    <jats:sub>50<\/jats:sub>\n                    of 38.25\u2009\u00b5M for T298875 and 29.11~35.3\u2009\u00b5M for O859585 in various HCV genotypes. We demonstrated that O859585 efficiently blocked HCV attachment by neutralizing free viral particles without affecting other stages of the HCV life cycle and interferon stimulation. O859585 interrupted binding between HCV E2 and CD81. Of note, co-treatment of O859585 with either interferon alpha (IFN\u03b1) or sofosbuvir exerted either an additive or synergistic antiviral activity in HCV-infected cells with no measurable effect on cell viability. Most importantly, O859585 in combination with IFN\u03b1 and sofosbuvir exhibited synergistic effects on anti-HCV activity in primary human hepatocytes. Collectively, these data suggest that O859585 may be a novel antiviral agent for HCV therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-43783-6","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T18:03:33Z","timestamp":1557770613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry"],"prefix":"10.1038","volume":"9","author":[{"given":"Lap P.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chorong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang T. D.","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Mee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Min","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han N.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huu C.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Sook","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon B.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"key":"43783_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/srep29969","volume":"6","author":"CY Chung","year":"2016","unstructured":"Chung, C. Y. et al. (4R,6S)-2-Dihydromenisdaurilide is a butenolide that efficiently inhibits hepatitis C virus entry. Sci. Rep. 6, 29969 (2016).","journal-title":"Sci. Rep."},{"key":"43783_CR2","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.4254\/wjh.v7.i26.2676","volume":"7","author":"AA Mohamed","year":"2015","unstructured":"Mohamed, A. A. et al. Hepatitis C virus: A global view. World J. Hepatol. 7, 2676\u20132680 (2015).","journal-title":"World J. Hepatol."},{"key":"43783_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.micinf.2009.12.012","volume":"12","author":"MA Joyce","year":"2010","unstructured":"Joyce, M. A. & Tyrrell, D. L. The cell biology of hepatitis C virus. Microbes Infect. 12, 263\u2013271 (2010).","journal-title":"Microbes Infect."},{"key":"43783_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.addr.2007.04.014","volume":"59","author":"T Suzuki","year":"2007","unstructured":"Suzuki, T., Ishii, K., Aizaki, H. & Wakita, T. Hepatitis C viral life cycle. Adv. Drug Deliv. Rev. 59, 1200\u20131212 (2007).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"43783_CR5","first-page":"211","volume":"13","author":"G Tsoulfas","year":"2009","unstructured":"Tsoulfas, G. et al. Hepatitis C and liver transplantation. Hippokratia. 13, 211\u2013215 (2009).","journal-title":"Hippokratia."},{"key":"43783_CR6","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405\u20132416 (2011).","journal-title":"N. Engl. J. Med."},{"key":"43783_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2217\/fvl.13.11","volume":"8","author":"M Lemoine","year":"2013","unstructured":"Lemoine, M., Nayagam, S. & Thursz, M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 8, 371\u2013380 (2013).","journal-title":"Future Virol."},{"key":"43783_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2009.05.138","volume":"386","author":"CM Wu","year":"2009","unstructured":"Wu, C. M. et al. Tylophorine arrests carcinoma cells at G1 phase by downregulating cyclin A2 expression. Biochem. Biophys. Res. Commun. 386, 140\u2013145 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"43783_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/0008-5472.CAN-03-1904","volume":"64","author":"W Gao","year":"2004","unstructured":"Gao, W. et al. Novel mode of action of tylophorine analogs as antitumor compounds. Cancer Res. 64, 678\u2013688 (2004).","journal-title":"Cancer Res."},{"key":"43783_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-2003-37021","volume":"69","author":"SK Lee","year":"2003","unstructured":"Lee, S. K., Nam, K. A. & Heo, Y. H. Cytotoxic activity and G2\/M cell cycle arrest mediated by antofine, a phenanthroindolizidine alkaloid isolated from Cynanchum paniculatum. Planta Med. 69, 21\u201325 (2003).","journal-title":"Planta Med."},{"key":"43783_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2012.07.006","volume":"57","author":"LV Pham","year":"2012","unstructured":"Pham, L. V., Ngo, H. T., Lim, Y. S. & Hwang, S. B. Hepatitis C virus non-structural 5B protein interacts with cyclin A2 and regulates viral propagation. J. Hepatol. 57, 960\u2013966 (2012).","journal-title":"J. Hepatol."},{"key":"43783_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature04083","volume":"436","author":"RS Brown","year":"2005","unstructured":"Brown, R. S. Hepatitis C and liver transplantation. Nature 436, 973\u2013978 (2005).","journal-title":"Nature"},{"key":"43783_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.antiviral.2016.07.002","volume":"132","author":"M Lee","year":"2016","unstructured":"Lee, M. et al. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. Antiviral Res. 132, 287\u2013295 (2016).","journal-title":"Antiviral Res."},{"key":"43783_CR14","doi-asserted-by":"publisher","first-page":"10073","DOI":"10.1128\/JVI.01707-15","volume":"89","author":"C Park","year":"2015","unstructured":"Park, C. et al. Pim kinase interacts with nonstructural 5A protein and regulates hepatitis C virus entry. J. Virol. 89, 10073\u201310086 (2015).","journal-title":"J. Virol."},{"key":"43783_CR15","doi-asserted-by":"crossref","unstructured":"Tai, C. J., Li, C. L., Tai, C. J., Wang, C. K. & Lin, L. T. Early viral entry assays for the identification and evaluation of antiviral compounds. J. Vis. Exp. e53124 (2015).","DOI":"10.3791\/53124"},{"key":"43783_CR16","doi-asserted-by":"crossref","unstructured":"Bianchi, A., Crotta, S., Brazzoli, M., Foung, S. K. & Merola, M. Hepatitis C virus E2 protein ectodomain is essential for assembly of infectious virions. Int. J. Hepatol. 968161 (2011).","DOI":"10.4061\/2011\/968161"},{"key":"43783_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.virol.2010.08.009","volume":"407","author":"S Liu","year":"2010","unstructured":"Liu, S. et al. The second extracellular loop dictates Occludin\u2010mediated HCV entry. Virology 407, 160\u2013170 (2010).","journal-title":"Virology"},{"key":"43783_CR18","doi-asserted-by":"publisher","first-page":"11290","DOI":"10.1074\/jbc.M110.194472","volume":"286","author":"YS Lim","year":"2011","unstructured":"Lim, Y. S. & Hwang, S. B. Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J. Biol. Chem. 286, 11290\u201311298 (2011).","journal-title":"J. Biol. Chem."},{"key":"43783_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1101\/gad.2.4.383","volume":"2","author":"DE Levy","year":"1988","unstructured":"Levy, D. E., Kessler, D. S., Pine, R., Reich, N. & Darnell, J. E. Jr. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 2, 383\u2013393 (1988).","journal-title":"Genes Dev."},{"key":"43783_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1872-034X.2007.00283.x","volume":"38","author":"T Saito","year":"2008","unstructured":"Saito, T. & Gale, M. Jr. Regulation of innate immunity against hepatitis C virus infection. Hepatol. Res. 38, 115\u2013122 (2008).","journal-title":"Hepatol. Res."},{"key":"43783_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/jac\/dkr588","volume":"67","author":"NJ Horscroft","year":"2012","unstructured":"Horscroft, N. J., Pryde, D. C. & Bright, H. Antiviral applications of Toll-like receptor agonists. J. Antimicrob. Chemother. 67, 789\u2013801 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"43783_CR22","first-page":"241","volume":"2","author":"L Zhao","year":"2010","unstructured":"Zhao, L., Au, J. L. & Wientjes, M. G. Comparison of methods for evaluating drug-drug interaction. Front. Biosci. 2, 241\u2013249 (2010).","journal-title":"Front. Biosci."},{"key":"43783_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/hep.24803","volume":"55","author":"N Calland","year":"2012","unstructured":"Calland, N. et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55, 720\u2013729 (2012).","journal-title":"Hepatology"},{"key":"43783_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.antiviral.2015.04.003","volume":"118","author":"WC Hsu","year":"2015","unstructured":"Hsu, W. C. et al. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. Antiviral Res. 118, 139\u2013147 (2015).","journal-title":"Antiviral Res."},{"key":"43783_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-82","volume":"12","author":"S Saraswati","year":"2013","unstructured":"Saraswati, S., Kanaujia, P. K., Kumar, S., Kumar, R. & Alhaider, A. A. Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis. Mol. Cancer 12, 82 (2013).","journal-title":"Mol. Cancer"},{"key":"43783_CR26","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1021\/jo00384a053","volume":"52","author":"JE Nordlander","year":"1987","unstructured":"Nordlander, J. E. & Njoroge, F. G. A short synthesis of (S)-(+)-tylophorine. J. Org. Chem. 52, 1627\u20131630 (1987).","journal-title":"J. Org. Chem."},{"key":"43783_CR27","first-page":"1164","volume":"15","author":"Z Jin","year":"2004","unstructured":"Jin, Z., Li, S. P., Wang, Q. M. & Huang, R. Q. A concise total synthesis of S-(+)-tylophorine. Chin. Chem. Lett. 15, 1164\u20131166 (2004).","journal-title":"Chin. Chem. Lett."},{"key":"43783_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.3","volume":"5","author":"XJ Qian","year":"2016","unstructured":"Qian, X. J., Zhu, Y. Z., Zhao, P. & Qi, Z. T. Entry inhibitors: New advances in HCV treatment. Emerg. Microbes Infect. 5, e3 (2016).","journal-title":"Emerg. Microbes Infect."},{"key":"43783_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/lt.20405","volume":"11","author":"GL Davis","year":"2005","unstructured":"Davis, G. L. et al. Collaborative Antiviral Study Group. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 11, 941\u2013949 (2005).","journal-title":"Liver Transpl."},{"key":"43783_CR30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/lt.20876","volume":"12","author":"TD Schiano","year":"2006","unstructured":"Schiano, T. D. et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 12, 1381\u20131389 (2006).","journal-title":"Liver Transpl."},{"key":"43783_CR31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/lt.21784","volume":"15","author":"RJ Firpi","year":"2009","unstructured":"Firpi, R. J. et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 15, 1063\u20131071 (2009).","journal-title":"Liver Transpl."},{"key":"43783_CR32","doi-asserted-by":"publisher","first-page":"e1001086","DOI":"10.1371\/journal.ppat.1001086","volume":"6","author":"CJ Baldick","year":"2010","unstructured":"Baldick, C. J. et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 6, e1001086 (2010).","journal-title":"PLoS Pathog."},{"key":"43783_CR33","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1128\/JVI.00586-11","volume":"85","author":"MC Sabo","year":"2011","unstructured":"Sabo, M. C. et al. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85, 7005\u20137019 (2011).","journal-title":"J. Virol."},{"key":"43783_CR34","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3389\/fmicb.2017.01129","volume":"8","author":"S Min","year":"2017","unstructured":"Min, S. et al. Abl tyrosine kinase regulates hepatitis C virus entry. Front Microbiol. 8, 1129 (2017).","journal-title":"Front Microbiol."},{"key":"43783_CR35","doi-asserted-by":"publisher","first-page":"9058","DOI":"10.1128\/JVI.00856-16","volume":"90","author":"S Nakajima","year":"2016","unstructured":"Nakajima, S. et al. Fungus-derived neoechinulin B as a novel antagonist of liver X receptor, identified by chemical genetics using a hepatitis C virus cell culture system. J. Virol. 90, 9058\u20139074 (2016).","journal-title":"J. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43783-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43783-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43783-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T19:58:59Z","timestamp":1721246339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43783-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43783"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43783-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,13]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7288"}}